FDA-Approved Botulinum Toxin Brands 2026: Botox vs Dysport vs Xeomin
Published: 2026-05-057 min
Author: Op. Dr. Oğuzhan Akgül
Comparison table
| Property | Botox | Dysport | Xeomin |
|---|---|---|---|
| Maker | Allergan / AbbVie | Galderma / Ipsen | Merz |
| Active | Onabotulinumtoxin A | Abobotulinumtoxin A | Incobotulinumtoxin A |
| Complexing proteins | Yes | Yes | No (pure) |
| Unit | Botox U | Speywood U | Botox U equivalent |
| Onset | 3–7 d | 2–5 d | 3–7 d |
| Peak | day 14 | day 14 | day 14 |
| Duration | 3–6 mo | 3–6 mo | 3–6 mo |
| Diffusion | Medium | Wider | Medium |
| FDA approval | 1989 | 2009 | 2010 |
Which is right for you?
- Botox — most clinical data; thin-line control, masseter, gummy smile.
- Dysport — wider diffusion profile; broad-area forehead, hyperhidrosis. Unit conversion: 1 Botox U ≈ 2.5–3 Dysport U.
- Xeomin — pure (no complexing proteins); useful for repeat-injection patients with potential antibody concerns.
Switching brands
Reasonable when an unexpected duration reduction suggests possible immunogenicity → consider Xeomin. Routine switching is unnecessary.
Bottom line
All three are safe and effective when used by a trained physician at a TİTCK-approved clinic. Brand choice is set during consultation based on anatomy and goal.
References
- FDA — Botulinum toxin product labeling
- EMA — Vistabel/Bocouture/Azzalure SmPC
- TİTCK — Botulinum toksin ürün listesi